Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

被引：8
|
作者：
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Clingan, Philip R.
Sriuranpong, Virote
Rizvi, Naiyer A.
McGinniss, Jennifer
Pouliot, Jean-Francois
Lee, Sue
Seebach, Frank A.
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[2] Baskent Univ, Dept Med Oncol, Adana, Turkey
[3] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey
[4] Istanbul Medeniyet Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[5] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[6] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, GA USA
[7] Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey
[8] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[9] Sverdlovsk Reg Oncol Ctr, Dept Radiotherapy, Ekaterinburg, Russia
[10] LLC EVIMED, Chelyabinsk, Russia
[11] Univ Wollongong, Wollongong Hosp, Illawarra Canc Ctr, Southern Med Day Care Ctr, Wollongong, NSW, Australia
[12] Univ Wollongong, Wollongong Hosp, Illawarra Canc Ctr, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia
[13] Chulalongkorn Univ, Fac Med, Dept Med, Div Med Oncol, Bangkok, Thailand
[14] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[15] Columbia Univ, Med Ctr, Div Hematol Oncol, New York, NY USA
[16] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9085
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Expression analysis of programmed cell death 1 ligand 1 (PD-L1) in patients with non-small cell lung cancer
    Peng, Nanqiu
    Qin, Liang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 15 (01): : 1 - 5
  • [22] Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
    Feliciano, Josephine Louella
    McLoone, Dylan
    Xu, Yingxin
    Quek, Ruben G. W.
    Kuznik, Andreas
    Pouliot, Jean-Francois
    Gullo, Giuseppe
    Rietschel, Petra
    Guyot, Patricia
    Konidaris, Gerasimos
    Chan, Keith
    Keeping, Sam
    Wilson, Florence R.
    Freemantle, Nick
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [23] Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Vecchiarelli, S.
    D'Incecco, A.
    Minuti, G.
    Gallo, M.
    De Luca, A.
    Landi, L.
    Bennati, C.
    Spreafico, M.
    D'Arcangelo, M.
    Attilia, L.
    Mazza, V.
    Normanno, N.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2389 - S2389
  • [24] Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC)
    Vecchiarelli, S.
    D'Incecco, A.
    Gallo, M.
    De Luca, A.
    Minuti, G.
    Landi, L.
    Bennati, C.
    Spreafico, M.
    D'Arcangelo, M.
    Attilia, L.
    Mazza, V.
    Normanno, N.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC)
    McLaughlin, Joseph
    Schalper, Kurt A.
    Carvajal-Hausdorf, Daniel E.
    Pelekanou, Vasiliki
    Velcheti, Vamsidhar
    Haack, Herbert
    Silver, Matthew R.
    Herbst, Roy
    LoRusso, Patricia
    Rimm, David L.
    CANCER RESEARCH, 2015, 75
  • [26] Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
    Baramidze, A.
    Makharadze, T.
    Gogishvili, M.
    Melkadze, T.
    Giorgadze, D.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    McIntyre, D.
    Kaul, M.
    Quek, R. G. W.
    Pouliot, J-F.
    Seebach, F.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
    Akinboro, Oladimeji
    Vallejo, Jonathon Joseph
    Nakajima, Erica C.
    Ren, Yi
    Mishra-Kalyani, Pallavi Shruti
    Larkins, Erin A.
    Vellanki, Paz J.
    Drezner, Nicole Lauren
    Mathieu, Luckson Noe
    Donoghue, Martha Boeri
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
    Cronin-Fenton, D.
    Dalvi, T.
    Hedgeman, E.
    Norgaard, M.
    Petersen, L.
    Hansen, H.
    Fryzek, J.
    Lawrence, D.
    Walker, J.
    Mellemgaard, A.
    Rasmussen, T.
    Shire, N.
    Rigas, J.
    Potter, D.
    Hamilton-Dutoit, S.
    Sorensen, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085
  • [29] Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
    Bondarenko, I.
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Mcginniss, J.
    Pouliot, J.
    Lee, S.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S951 - S951
  • [30] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
12345